ERASCA, INC. SECURITIES FRAUD NOTICE: Berger Montague Informs Erasca, Inc. (ERAS) Investors of a Securities Fraud Lawsuit

National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Erasca, Inc. (NASDAQ: ERAS) ("Erasca" or the "Company") on behalf of investors who purchased or acquired Erasca common stock during the period from January 14, 2025 through April 26, 2026 (the "Class Period"). Investor Deadline: Investors who purchased or acquired Erasca securities during the Class Period may, no later than August 10, 2026 , seek to be appointed as a lead plaintiff representative of the class. Headquartered in San Diego, Calif., Erasca is a clinical-stage precision oncology company developing therapies targeting the RAS/MAPK pathway. The Company's lead drug candidate, ERAS-0015, is a pan-RAS molecular glue in clinical development for patients with RAS-mutated solid tumors. According to the suit, Defendants publicly promoted ERAS-0015 as a potential "best-in-class" therapy and repeatedly touted its purportedly superior preclinical results comparatively to Revolution Medicines, Inc.'s RMC-6236. On April 27, 2026, the truth emerged. Erasca disclosed that Revolution Medicines had accused the Company of patent infringement, trade secret misappropriation, and making deceptive comparative statements about ERAS-0015. Later that day, Erasca reported preliminary clinical data that included a patient death and admitted its comparisons with competing therapies relied on cross-study analyses rather than head-to-head trials. Erasca's stock plummeted more than 45% on the news.